Sign in
SCHEDULE 13G/A

Statement of Beneficial Ownership

C4 Therapeutics, Inc. Filed Acc 0002050709-26-000030

Stakes reported in this filing

Reporting person Shares Of the class
Squadron Master Fund LP 9,718,683 7.9%
Squadron Capital Management LLC 9,718,683 7.9%
Matthew Sesterhenn 9,718,683 7.9%
William Blank 9,718,683 7.9%

Members of a group can each report the same shares, so these rows overlap and don't add up.

Loading xslSCHEDULE_13G_X02/primary_doc.xml…